Vinpocetine

Phase 3Small molecule

SStanford University

Vinpocetine is one of 42 small molecule programs targeting Diabetic Nephropathy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Diabetic NephropathyRecruiting

Fetal Alcohol Spectrum DisordersNot yet recruiting

Diabetic NephropathyPhase 3

Recruiting

Fetal Alcohol Spectrum DisordersPhase 1

Not yet recruiting

Competition

Competitive Landscape

49 competitors in Diabetic Nephropathy

#DrugCompanyPhaseTrials

Aldactone

Pfizer

Approved

6 2

Farxiga

AstraZeneca

Approved

3 3

Avapro

Sanofi

Approved

1 4

Byetta

AstraZeneca

Approved

1 5

Zemplar

AbbVie

Approved

1 6

Lorelco

Sanofi

Approved

1 7

Rocaltrol

Jazz Pharmaceuticals

Approved

1 8

Kerendia

Defitelio

Corlanor

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2/3Recruiting

Parkinson

NCT07229664

Clinical

Trials by Indication[1]

Epilepsy1 trial

Cognitive Effects of Vinpocetine in Healthy Adults and Patients With Epilepsy

Suspended·SStanford University·Phase 1/2·NCT02011971·30 enrolled

Parkinson1 trial

Vinpocetine in Patients With Parkinsonian Disease

Recruiting·TTanta University·Phase 2/3·NCT07229664·60 enrolled

Diabetic Nephropathy1 trial

Clinical Outcome of Vinpocetine in Diabetic Nephropathy

Recruiting·—·Phase 2/3·NCT06441591·64 enrolled

Ischemic stroke1 trial

Vinpocetine Inhibits NF-κB-dependent Inflammation in Acute Ischemic Stroke Patients

Completed·TTianjin Medical University General Hospital·Phase 2/3·NCT02878772·60 enrolled

Unspecified1 trial

Dose Escalation Study of Vinpocetine in Healthy Volunteers

Not yet recruiting·SStanford University·Phase 1·NCT06635746·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Vinpocetine. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Vinpocetine compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Vinpocetine. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Stanford University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: SStanford University

Vinpocetine

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Epilepsy1 trial

Parkinson1 trial

Diabetic Nephropathy1 trial

Ischemic stroke1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News